ArticleBMC proceedings2025
Accelerating HPV-related cancer elimination - a meeting report.
Article in BMC proceedings, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
The human papillomavirus (HPV) Prevention and Control Board organized a meeting to explore effective strategies for accelerating the elimination of HPV-related cancers, starting from WHO's cervical cancer elimination campaign targets-vaccination of 90% of girls by age 15, two HPV screenings with a high-performance test for 70% of women between 35-45 years, and 90% treatment and care of women with cervical disease. Nevertheless, the global HPV vaccination coverage remains low (~ 30%), as does screening coverage, with only 24% (48/139) of programmes utilising recommended high-performance tests (such as HPV testing). The meeting explored various strategies, including the extension of vaccination for women at older ages. While vaccination of HPV-positive individuals has demonstrated safety and immunogenicity, further research is required to confirm the potential protective effects and reduced viral transmission among infected populations. Several innovative approaches were discussed, including the HPV Faster strategy, promoting combined HPV vaccination and screening for women up to age 45. This strategy aims to substantially reduce cervical cancer incidence by decreasing future screening needs among HPV-negative women and intensifying follow-up for those already HPV-positive. A variant of this approach, Sweden's "HPV EVEN Faster," simultaneously vaccinates and screens younger women (ages 23-30), aiming at significantly reducing HPV circulation and effectively reaching underserved populations. Moreover, in resource-limited settings, transitioning to single-dose vaccination emerged as a promising strategy to expand vaccine coverage, as modelled in India, Rwanda, and Brazil. Modelling data reinforced the prioritisation of increasing vaccination coverage and expanding targets in girls up to age 20 as the most efficient strategy to reduce cervical cancers. However, when increasing coverage is challenging, extending vaccination to boys could potentially enhance herd protection. Finally, the discussions underlined that successful "accelerated" HPV elimination strategies must be context-specific, taking into consideration local resources, health system capacities, and socio-economic factors. Political commitment, targeted implementation research, and innovations such as affordable new vaccines and point-of-care tests are key to speed up global progress toward HPV-related cancer elimination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.